Indian court locks dasatinib generic amid "bald" defence
This article was originally published in Scrip
An Indian court has maintained a restraining order against certain BDR group firms in a patent infringement case concerning Bristol- Myers Squibb's anticancer, Sprycel (dasatinib), though it appears to have left the door somewhat ajar on whether or not the monohydrate form of the compound is covered in the suit patent.
You may also be interested in...
A new report on the preparedness of 10 APAC nations to tackle a mounting cancer burden identifies gaps that need to be addressed, saying that a focus on prevention and early diagnosis could help, while also touching on issues around regional drug availability.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.
India clears Opdivo patent, turning down pre-grant representations from four opposing parties including Dr Reddy's. The patent office rejected the opponents' arguments including those around obviousness and "inherent anticipation."